The problem with the marlket looking ugly is, just as fast as it went down it can go right back up. Keep your intestinal fortitude and be ready for the bounce. if you got some cash GREAT! Wait till shes moving back up and buy in then. I wish I had some cash! All tied up and not in a good way either :)
Not having cash on sidelines to take advantage when this stops bleeding. A serious average down can make some big money in a short time. We know this is a great fund. Id hate to sell and then be on a 90 day cant buy list when it bounces.....yes its hard to watch but remember, it WILL come back. Heading close to 52 week low. This fund goes to 100 I will remortgage my house!!!
Because one bad apple dont spoil the whole bunch! Some drugs have to be high priced to recoup R&D investments and record a profit after years and years of trials! Regulate the generics and get off the companys backs who actually produce life saving drugs like Gilead! All this red today for the top holdings not looking like a nice close today. IBB is down about 12 bucks. hate to sell but hate to wait and see it go lower. UGH
Jobs shipped overseas to low wage countries. Tax shelters, CEOs paying nothing in taxes! IS this for real? Damn right and its time we do something to change this country!
By the way IBIO is a Gates Foundation company. Recall CVM could never get that?
NEW YORK, NY--(Marketwired - Aug 11, 2015) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biopharmaceutical products, received notice that its application for a U.S. patent for a monoclonal antibody targeting influenza is scheduled to result in issuance of a new patent on August 26.
The patent, US 9,155,201 entitled "Human Neuraminidase Antibody and Methods of Use Thereof," includes claims for a method for treating influenza infection using a monoclonal antibody against the influenza neuraminidase protein. Neuraminidase is an influenza protein that is essential for viral replication and release from cells. Antibodies based on this invention are potential therapeutic agents against highly pathogenic H5N1 influenza, including strains resistant to drugs such as oseltamivir (marketed as Tamiflu®), and have blocked the replication of multiple influenza strains, including drug-resistant isolates. These and other anti-influenza antibodies have been produced using iBio's proprietary iBioLaunch™ technology, and have demonstrated safety and therapeutic efficacy in highly predictive animal models infected with a variety of influenza types.